Linaprazan glurate
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Linaprazan glurate
- Molecular weight
- 480.57
- Structure (SMILES)
- Cc1cccc(C)c1CNc1cc(C(=O)NCCOC(=O)CCCC(=O)O)cn2c(C)c(C)nc12
- 14c x842
- glurate de linaprazan
- Glurate de linaprazan
- glurato de linaprazan
- Glurato de linaprazan
- linaprazan glurate
- Linaprazan glurate
- linaprazan glurate [INN]
- LINAPRAZAN GLURATE [USAN]
- Linaprazan glurate [WHO-DD]
- linaprazan glurate 25 mg bid
- linaprazan glurate 25 mg BID
- linaprazan glurate 25 mg qd
- linaprazan glurate 25 mg QD
- linaprazan glurate 50 mg bid
- linaprazan glurate 50 mg BID
- linaprazan glurate 50 mg qd
- linaprazan glurate 50 mg QD
- linaprazan glurate 75 mg bid
- linaprazan glurate 75 mg BID
- linaprazan glurate 75 mg qd
- linaprazan glurate 75 mg QD
- linaprazan glurate capsules
- Linaprazan Glurate Capsules
- linaprazan glurate inn
And 11 more, listed on the interactive page.
- CAS registry numbers
- 1228559-81-6
- ChEMBL ID
- CHEMBL5095187
- InChIKey
- GPHPBXRKAJSSIC-UHFFFAOYSA-N
- PubChem compound IDs
- 46208366
- FDA ingredient codes (UNII)
- 3VG4D399DT
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -prazan
Investigated indications
- Condition
- Gastroesophageal Reflux
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003948
- Subject identifier
- D005764
- Condition identifier
- EFO_0003948
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006781
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0007186
- Highest recorded phase
- 3
- NCT05469854
- NCT05742984
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 3
- Polar surface area
- 122.03
- Calculated partition coefficient (ALogP)
- 3.71
- Calculated partition coefficient (XLogP)
- 3.7
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 11
- Heavy atoms
- 35
- Molecular formula
- C26H32N4O5
- Monoisotopic mass
- 480.23727013
- Natural product
- No
Related records
Trials (13)
- A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
- A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)
- A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
- A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate
- Drug Interaction Study on Linaprazan Glurate Capsules
- Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam
- Investigate Linaprazan Glurate/Linaprazan in Healthy Subjects
- Mass Balance Study of [14C]X842 in Healthy Adult Male Subjects
- Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study
- Single-dose and Multiple-dose X842 Phase 1 Study
- Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis
- The Phase III Clinical Trial of X842 Capsules for Reflux Esophagitis